185 related articles for article (PubMed ID: 29904440)
1. Serum Free Light Chains in Neoplastic Monoclonal Gammopathies: Relative Under-Detection of Lambda Dominant Kappa/Lambda Ratio, and Underproduction of Free Lambda Light Chains, as Compared to Kappa Light Chains, in Patients With Neoplastic Monoclonal Gammopathies.
Lee WS; Singh G
J Clin Med Res; 2018 Jul; 10(7):562-569. PubMed ID: 29904440
[TBL] [Abstract][Full Text] [Related]
2. Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio.
Singh G
J Clin Med Res; 2017 Jan; 9(1):46-57. PubMed ID: 27924175
[TBL] [Abstract][Full Text] [Related]
3. Serum Free Light Chain Assay and κ/λ Ratio Performance in Patients Without Monoclonal Gammopathies: High False-Positive Rate.
Singh G
Am J Clin Pathol; 2016 Aug; 146(2):207-14. PubMed ID: 27473738
[TBL] [Abstract][Full Text] [Related]
4. Quantification of Free Immunoglobulin Light Chains in Urine.
Singh G; Cotter T; Ye Mon M; Xu H; Bollag RJ
J Appl Lab Med; 2023 Nov; 8(6):1101-1114. PubMed ID: 37725944
[TBL] [Abstract][Full Text] [Related]
5. A comparison between high resolution serum protein electrophoresis and screening immunofixation for the detection of monoclonal gammopathies in serum.
Smith J; Raines G; Schneider HG
Clin Chem Lab Med; 2018 Jan; 56(2):256-263. PubMed ID: 28787269
[TBL] [Abstract][Full Text] [Related]
6. Can serum free light chains replace urine electrophoresis in the detection of monoclonal gammopathies?
Beetham R; Wassell J; Wallage MJ; Whiteway AJ; James JA
Ann Clin Biochem; 2007 Nov; 44(Pt 6):516-22. PubMed ID: 17961305
[TBL] [Abstract][Full Text] [Related]
7. Oligoclonal Pattern/Abnormal Protein Bands in Post-Treatment Plasma Cell Myeloma Patients: Implications for Protein Electrophoresis and Serum Free Light Chain Assay Results.
Singh G
J Clin Med Res; 2017 Aug; 9(8):671-679. PubMed ID: 28725315
[TBL] [Abstract][Full Text] [Related]
8. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays.
Katzmann JA; Dispenzieri A; Kyle RA; Snyder MR; Plevak MF; Larson DR; Abraham RS; Lust JA; Melton LJ; Rajkumar SV
Mayo Clin Proc; 2006 Dec; 81(12):1575-8. PubMed ID: 17165636
[TBL] [Abstract][Full Text] [Related]
9. Comparison of serum immunofixation electrophoresis and free light chain assays in the detection of monoclonal gammopathies.
Wood PB; McElroy YG; Stone MJ
Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):278-80. PubMed ID: 20709664
[TBL] [Abstract][Full Text] [Related]
10. Serum and Urine Protein Electrophoresis and Serum-Free Light Chain Assays in the Diagnosis and Monitoring of Monoclonal Gammopathies.
Singh G
J Appl Lab Med; 2020 Nov; 5(6):1358-1371. PubMed ID: 33150391
[TBL] [Abstract][Full Text] [Related]
11. Serum free light chain assay reduces the need for serum and urine immunofixation electrophoresis in the evaluation of monoclonal gammopathy.
Fulton RB; Fernando SL
Ann Clin Biochem; 2009 Sep; 46(Pt 5):407-12. PubMed ID: 19641008
[TBL] [Abstract][Full Text] [Related]
12. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.
Katzmann JA; Clark RJ; Abraham RS; Bryant S; Lymp JF; Bradwell AR; Kyle RA
Clin Chem; 2002 Sep; 48(9):1437-44. PubMed ID: 12194920
[TBL] [Abstract][Full Text] [Related]
13. Differences identified between serum and urine immunofixation electrophoresis.
Tracy E; Andrews DM; Constantin MA; Zhu Y
Clin Chim Acta; 2015 Jan; 439():68-70. PubMed ID: 25307209
[TBL] [Abstract][Full Text] [Related]
14. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
[TBL] [Abstract][Full Text] [Related]
15. Serum Free Light Chain Assay in Monoclonal Gammopathic Manifestations.
Lee WS; Singh G
Lab Med; 2019 Oct; 50(4):381-389. PubMed ID: 30957173
[TBL] [Abstract][Full Text] [Related]
16. Multiple myeloma: Detection of free monoclonal light chains by modified immunofixation electrophoresis with antisera against free light chains.
Wilhite D; Arfa A; Cotter T; Savage NM; Bollag RJ; Singh G
Pract Lab Med; 2021 Nov; 27():e00256. PubMed ID: 34703870
[TBL] [Abstract][Full Text] [Related]
17. Detection of kappa and lambda light chain monoclonal proteins in human serum: automated immunoassay versus immunofixation electrophoresis.
Jaskowski TD; Litwin CM; Hill HR
Clin Vaccine Immunol; 2006 Feb; 13(2):277-80. PubMed ID: 16467338
[TBL] [Abstract][Full Text] [Related]
18. A rare case of IgE kappa monoclonal gammopathy of undetermined significance identified in a Swedish female.
Fager Ferrari M; Lemonakis K; Förnvik Jonsson M
Scand J Clin Lab Invest; 2021 Sep; 81(5):385-388. PubMed ID: 34097568
[TBL] [Abstract][Full Text] [Related]
19. The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies.
Greil C; Ihorst G; Gaiser F; Salzer U; Bisse E; Kastritis E; Ludwig H; Wäsch R; Engelhardt M
Eur J Haematol; 2017 Nov; 99(5):449-458. PubMed ID: 28886228
[TBL] [Abstract][Full Text] [Related]
20. Quantification by Ultrafiltration and Immunofixation Electrophoresis Testing for Monoclonal Serum Free Light Chains.
Singh G; Bollag R
Lab Med; 2020 Nov; 51(6):592-600. PubMed ID: 32285117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
